Adriana Sumoza-Toledo , Mario Iván Espinoza-Gabriel , Dvorak Montiel-Condado
{"title":"Evaluation of the TRPM2 channel as a biomarker in breast cancer using public databases analysis","authors":"Adriana Sumoza-Toledo , Mario Iván Espinoza-Gabriel , Dvorak Montiel-Condado","doi":"10.1016/j.bmhime.2017.11.038","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Breast cancer is one of the most common malignancies affecting women. Recent investigations have revealed a major role of ion channels in cancer. The transient receptor potential melastatin-2 (TRPM2) is a plasma membrane and lysosomal channel with important roles in cell migration and cell death in immune cells and tumor cells.</p></div><div><h3>Methods</h3><p>In this study, we investigated the prognostic value of TRPM2 channel in breast cancer, analyzing public databases compiled in Oncomine™ (Thermo Fisher, Ann Arbor, MI) and online Kaplan-Meier Plotter platforms.</p></div><div><h3>Results</h3><p>The results revealed that TRPM2 mRNA overexpression is significant <em>in situ</em> and invasive breast carcinoma compared to normal breast tissue. Furthermore, multi-gene validation using Oncomine™ showed that this channel is coexpressed with proteins related to cellular migration, transformation, and apoptosis. On the other hand, Kaplan-Meier analysis exhibited that low expression of TRPM2 could be used to predict poor outcome in ER- and HER2+ breast carcinoma patients.</p></div><div><h3>Conclusions</h3><p>TRPM2 is a promising biomarker for aggressiveness of breast cancer, and a potential target for the development of new therapies.</p></div>","PeriodicalId":100195,"journal":{"name":"Boletín Médico Del Hospital Infantil de México (English Edition)","volume":"73 6","pages":"Pages 397-404"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bmhime.2017.11.038","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Boletín Médico Del Hospital Infantil de México (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2444340917001121","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Breast cancer is one of the most common malignancies affecting women. Recent investigations have revealed a major role of ion channels in cancer. The transient receptor potential melastatin-2 (TRPM2) is a plasma membrane and lysosomal channel with important roles in cell migration and cell death in immune cells and tumor cells.
Methods
In this study, we investigated the prognostic value of TRPM2 channel in breast cancer, analyzing public databases compiled in Oncomine™ (Thermo Fisher, Ann Arbor, MI) and online Kaplan-Meier Plotter platforms.
Results
The results revealed that TRPM2 mRNA overexpression is significant in situ and invasive breast carcinoma compared to normal breast tissue. Furthermore, multi-gene validation using Oncomine™ showed that this channel is coexpressed with proteins related to cellular migration, transformation, and apoptosis. On the other hand, Kaplan-Meier analysis exhibited that low expression of TRPM2 could be used to predict poor outcome in ER- and HER2+ breast carcinoma patients.
Conclusions
TRPM2 is a promising biomarker for aggressiveness of breast cancer, and a potential target for the development of new therapies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
